Alphamab Oncology swings to FY26 H1 loss of RMB 40.46 million; revenue falls 15.09% to RMB 271.24 million

• Alphamab Oncology posted a loss of RMB 40.46 million, swinging from a profit of RMB 21.58 million.
• Revenue fell to RMB 271.24 million from RMB 319.44 million.
• R&D expenses rose to RMB 255.04 million from RMB 253.16 million.
• KN026 won NMPA approval in HER2+ gastric/GEJ cancer, completing first commercial shipments and entering clinical use.
• Pathos AI licensed ex-China rights to JSKN016, featuring a US$125 million upfront and up to US$2.09 billion in milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12303385), on August 27, 2026, and is solely responsible for the information contained therein.